Molecular mechanisms involved in chemoprevention of black raspberry extracts: From transcription factors to their target genes

Nutrition and Cancer

Volumn 54, Issue 1, 2006, Pages 69-78

  Lu, Haitian ^a   Li, Jingxia ^a   Zhang, Dongyun ^a   Stoner, Gary D ^b   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLACK RASPBERRY EXTRACT; CYCLOOXYGENASE 2; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHANOL; MITOGEN ACTIVATED PROTEIN KINASE; PLANT EXTRACT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; BLACK RASPBERRY; CANCER; CANCER PREVENTION; CELL LINE; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPIDERMIS CELL; FREEZE DRYING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RASPBERRY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR PROMOTION;

ANIMALS; ANTICARCINOGENIC AGENTS; BENZOPYRANS; CELL LINE; CYCLOOXYGENASE 2; EPOXY COMPOUNDS; FRUIT; GENE EXPRESSION; METHANOL; MICE; NF-KAPPA B; PHYTOTHERAPY; PLANT EXTRACTS; ROSACEAE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RODENTIA; RUBUS; RUBUS OCCIDENTALIS;

EID: 33746558027     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5401_8     Document Type: Conference Paper

References (97)

1. Block G, Patterson B, and Subar A: Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18, 1-29, 1992.
2. Vecchia CL, and Tavani A: Fruit and vegetables, and human cancer. Eur J Cancer Prev 7, 3-8, 1998.
3. Xue H, Aziz RM, Sun N, Cassady JM, Kamendulis LM, et al.: Inhibition of cellular transformation by berry extracts. Carcinogenesis 2, 351-356, 2001.
4. Ahmed S, Rahman A, Mathur M, Athar M, and Sultana S: Anti-tumor promoting activity of Asteracantha longifolia against experimental hepatocarcinogenesis in rats. Food Chem Toxicol 39, 19-28, 2001.
5. Kusamran WR, Ratanavila A, and Tepsuwan A: Thai and Chinese bitter gourd fruits and sweet basil leaves on hepatic monooxygenases and glutathione S-transferase activities, and in vitro metabolic activation of chemical carcinogenesis in rats. Food Chem Toxicol 36, 475-484, 1998.
6. Gotoh T, Yamada K, Yin H, Ito A, Kataoka T, et al.: Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. Jpn J Cancer Res 89, 137-142, 1998.
7. Mukhtar H, and Ahmad N: Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol 158, 207-210, 1999.
8. Krishnan K, Ruffin MT, IV, and Brenner DE: Cancer chemoprevention: a new way to treat cancer before in happens. Primary Care 25, 361-319, 1998.
9. Watternberg LW: An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med 216, 133-141, 1997.
10. Rock CL: Nutritional factors in cancer chemoprevention. Hematol Oncol Clin North Am 12, 975-991, 1998.
11. Kresty LA, Morse MA, Morgan C, Carlton PS, Lu J, et al.: Chemoprevention of esophageal tumorigenesis by dietary administration of lyophilized black raspberries. Cancer Res 61, 6112-6119, 2001.
12. Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, et al.: Anti-angiogenic property of edible berries. Free Rad Res 36, 1023-1031, 2002.
13. McCarty MF: Current prospects for controlling cancer growth with non-cytotoxic agents-nutrients, phytochemicals, herbal extracts, and available drugs. Med Hypotheses 56, 137-154, 2001.
14. Cao G, and Prior RL: Anthocyanins are detected in human plasma after oral administration of an elderberry extract. Clin Chem 45, 574-576, 1999.
15. Viljanen K, Kylli P, Kivikari R, and Heinonen M: Inhibition of protein and lipid oxidation in liposomes by berry phenolics. J Agric Food Chem 52, 7419-7424, 2004.
16. Olsson ME, Gustavsson KE, Andersson S, Nilsson A, and Duan RD: Inhibition of cancer cell proliferation in vitro by fruit and berry extracts and correlations with antioxidant levels. J Agric Food Chem 52, 7264-7271, 2004.
17. Stoner GD, Kresty LA, Carlton PS, Siglin JC, and Morse MA: Isothiocyanates and freeze-dried strawberries as inhibitors of esophageal cancer. Toxicol Sci 52 (Suppl.), 95-100, 1999.
18. Carlton PS, Kresty LA, Siglin JC, Morse MA, Lu J, et al.: Inhibition of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus by dietary freeze-dried strawberries. Carcinogenesis 22, 441-446, 2001.
19. Atalay M, Gordillo G, Roy S, Rovin B, Bagchi D, et al.: Anti-angiogenic property of edible berry in a model of hemangioma. FEBS Lett 544, 252-257, 2003.
20. Mandal S and Stoner GD: Inhibition of N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis 11, 55-61, 1990.
21. Teel RW, Dixit R, and Stoner GD: The effects of ellagic acid on the uptake, persistence, metabolism and DNA-binding of benzo[a]pyrene in cultured explants of strain A/J mouse lung. Carcinogenesis 6, 391-395, 1985.
22. Teel RW: Ellagic acid binding to DNA as a possible mechanism for its antimutagenic and anticarcinogenic action. Cancer Lett 30, 329-336, 1986.
23. Ahn D, Putt D, Kresty L, Stoner GD, Fromm D, et al.: The effects of dietary ellagic acid on rat hepatic and esophageal mucosal cytochromes P450 and phase II enzymes. Carcinogenesis 17, 821-828, 1996.
24. Eferl E, and Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3, 859-867, 2003.
25. Lin A, and Karin M: NFκB in cancer: a market target. Semin Cancer Biol 13, 107-114, 2003.
26. Jauliac S, Lopez-Rodriguez C, Shaw LM, Brown LF, Rao A, et al.: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 4, 540-544, 2002.
27. Yan Y, Ouyang W, Li J, Ma Q, Hu Y et al.: Nuclear factor of activated T cells 3 (NFAT3) is specifically required for tumor necrosis factor-α (TNF-α)-induced cyclooxygenase-2 (COX-2) expression and cell transformation in C141 cells. J Cell Science, in press.
28. Huang C, Li J, Song L, Zhang D, Tong OS, et al.: Black rasberry extracts inhibit benzo[a]pyrene diol-epoxide-induced AP-1 activation and VEGF transcription by targeting the PI-3K/Akt pathway. Cancer Res 66, 581-587, 2006.
29. Li J, Chen H, Tang MS, Shi X, Amin S, et al.: PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal C141 cells. J Cell Biol 165, 77-86, 2004.
30. Bernstein LR, and Colburn NH: AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 244, 566-569, 1989.
31. Dhar A, Young MR, and Colburn NH: The role of AP-1, NFκB, and ROS/NOS in carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 234/235, 185-193, 2002.
32. Huang C, Huang Y, Li J, Hu W, Aziz R, et al.: Inhibition of benzo[a]pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor κB by black raspberry extracts. Cancer Res 62, 6857-6863, 2002.
33. Phillips DH: Fifty years of benzo[a]pyrene. Nature 303, 468-472, 1983.
34. Hanelt S, Helbig R, Hartmann A, Lang M, Seidel A, et al.: A comprehensive investigation of DNA adducts, DNA strand breaks and gene mutations induced by benzo[a]pyrene and (+/-)-antibenzo[a]pyrene-7,8-diol 9,10-oxide in cultured human cells. Mutat Res 390, 179-188, 1997.
35. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, et al.: Targeting of lung cancer mutation hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 92, 803-811, 2000.
36. Li J, Tang MS, Liu B, Shi X, and Huang C: A critical role of PI-3K/Akt/JNKs pathway in benzo[a]pyrene diol-epoxide (B[a]PDE)-induced AP-1 transactivation in mouse epidermal C141 cells. Oncogene 23, 3932-3944, 2004.
37. Shaulian E, and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-E136, 2002.
38. Angel P, and Karin M: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072, 465-469, 2002.
39. Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, et al.: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NFκB. EMBO J 21, 4104-4113, 2002.
40. Johnson R, Spiegelman B, Hanahan D, and Wisdom R: Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16, 4504-4511, 1996.
41. Li J, Chen H, Ke Q, Feng Z, Tang MS, et al.: Differential effects of polycyclic aromatic hydrocarbons on transactivation of AP-1 and NFκB in mouse epidermal C141 cells. Mol Carcinog 40, 104-115, 2004.
42. Sayer JM, Yagi H, Wood A, Conney AH, and Jerina DM: Extremely facile reaction between the ultimate carcinogen benzo(a)pyrene-7,8-diol 9,10-epoxide and ellagic acid. J Amer Chem Soc 104, 5562-5564, 1982.
43. Karin M, Liu Z, and Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9, 240-246, 1997.
44. Karin M, and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NFκB activity. Annu Rev Immunol 18, 621-663, 2000.
45. Li Q, and Verma M: NFκB regulation in the immune system. Nat Rev Immunol 2, 725-734, 2002.
46. Karin M, Cao Y, Greten FR, and Li ZW: NFκB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2, 301-310, 2002.
47. Viatour P, Merville MP, Bours V, and Chariot A: Phosphorylation of NFκB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 30, 43-52, 2005.
48. Romashkova JA, and Makarov SS: NFκB is a target of Akt in anti-apoptotic PDGF signaling. Nature 401, 86-90, 1999.
49. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, et al.: NFκB activation by tumor necrosis factor requires the Akt serine-threonine kinase, Nature 401, 82-85, 1999.
50. Rincon M, and Flavell RA: Transcription mediated by NFAT is highly inducible in effector CD4+ T helper 2 (Th2) cells but not in Th1 cells. Mol Cell Biol 17, 1522-1534, 1997.
51. Durand DB, Shaw JP, Bush MR, Replogle RE, Belagaje R, et al.: Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol Cell Biol 8, 1715-1724, 1988.
52. Serfling E, Barthelmas R, Pfeuffer I, Schenk B, Zarius S, et al.: Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocytes. EMBO J 8, 465-473, 1989.
53. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, et al.: Identification of a putative regulator of early T cell activation genes. Science 241, 202-205, 1988.
54. Rao A, Luo C, and Hogan PG: Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 15, 707-747, 1997.
55. Huang C, Mattjus P, Ma WY, Rincon M, Chen NY, et al.: Involvement of nuclear factor of activated T cells activation in UV response. Evidence from cell culture and transgenic mice. J Biol Chem 275, 9143-9149, 2000.
56. Huang C, Li J, Costa M, Zhang Z, Leonard SS, et al.: Hydrogen Peroxide Mediates Activation of Nuclear Factor of Activated T Cells (NFAT) by Nickel Subsulfide. Cancer Res 61, 8051-8057, 2001.
57. Huang C, Ding M, Li J, Leonard SS, Rojanasakul Y, et al.: Vanadium-induced nuclear factor of activated T cells through hydrogen peroxide. J Biol Chem 276, 22397-22403, 2001.
58. Chow CW, Rincon M, Cavanagh J, Dickens M, and Davis RJ: Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278, 1638-1641, 1997.
59. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, and Fresno M: An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275, 23627-23635, 2000.
60. Miyoshi C, and Ohshima N: Vascular endothelial growth factor (VEGF) expression regulates angiogenesis accompanying tumor growth in a peritoneal disseminated tumor model. In Vivo 15, 233-238, 2001.
61. Ferrara N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56, 794-814, 1999.
62. Carmeliet P, and Jain RK: Angiogenesis in cancer and other diseases. Nature 407, 249-257, 2000.
63. Xu L, Fukumura D, and Jain RK: Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MARK signaling pathway. J Biol Chem 277, 11368-11374, 2002.
64. Ferrara N, and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18, 4-25, 1997.
65. Ferrara N, and Bunting S: Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 5, 35-44, 1996.
66. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31, 1995.
67. Neufeld G, Cohen T, Gengrinovitch S, and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9-22, 1999.
68. Angelov L, Salhia B, Roncari L, McMahon G, and Guha A: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res 59, 5536-5541, 1999.
69. Borgstrom P, Hillan KJ, Sriramarao P, and Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neuralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56, 4032-4039, 1996.
70. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60, 5117-5124, 2000.
71. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, et al.: Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93, 8502-8507, 1996.
72. Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, et al.: c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro, Proc Natl Acacl Sci USA 96, 9671-9676, 1999.
73. Damert A, Ikeda E, and Risau W: Activator-protein-1 binding potentiates the HIF-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 327, 419-423, 1997.
74. Shibata A, Nagaja T, Imai T, Funahashi H, Nakao A, et al.: Inhibition of NFkappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 73, 237-243, 2002.
75. Qkamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, et al.: Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 16, 1928-1930, 2002.
76. Gao N, Shen L, Zhang Z, Leonard SS, He H, et al.: Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem 255, 33-45, 2004.
77. Fang J, Xia C, Cao Z, Zheng JZ, Reed E, et al.: Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19, 342-353, 2005.
78. Zhong XS, Zheng JZ, Reed E, andJiang BH: SU5416 inhibited VEGF and HIF-1α expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 324, 471-480, 2004.
79. Williams CS, Mann M, and Dubois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18, 7908-7916, 1999.
80. Nathan C: Points of control in inflammation. Nature 420, 846-852, 2002.
81. Tsujii M, and Dubois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501, 1995.
82. Tsujii M, Kawano S, and Dubois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94, 3336-3340, 1997.
83. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, et al.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164, 820-825, 2000.
84. Prescott SM, and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470, M69-78, 2000.
85. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, et al.: Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188, 1994.
86. Ristimaki A, Honkanen N, Jankala H, Sipponen P, and Harkonen M: Expression of cyclooxygenase 2 in human gastric cancer. Cancer Res 57, 1276-1280, 1997.
87. Hwang D, Scollard D, Byrne J, and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90, 455-460, 1998.
88. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, et al.: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clinical Cancer Res 5, 2018-2024, 1999.
89. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, et al.: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58, 3761-3764, 1998.
90. Guo YS, Hellmich MR, Wen XD, and Townsend CM, Jr: Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells. J Biol Chem 276, 22941-22947, 2001.
91. Subbaramaiah K, Lin DT, Hart JC, and Dannenberg AJ: Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 216, 12440-12448, 2002.
92. Subbaramaiah K, Norton L, Gerald W, and Dannenberg AJ: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277, 18649-18857, 2002.
93. de Gregorio R, Iniguez MA, Fresno M, and Alemany S: Cot kinase induces cyclooxygenase-2 expression in T cells through activation of nuclear factor of activated T cells. J Biol Chem 276, 27003-27009, 2001.
94. Sugimoto T, Haneda M, Sawano H, Isshiki K, Maeda S, et al.: Endothelin-1 induces cyclooxygenase-2 expression via nuclear factor of activated T-cell transcription factor in glomerular mesangial cells. J Am Soc Nephrol 12, 1359-1368, 2001.
95. Chun KS, Kim SH, Song YS, and Surh YJ: Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis 25, 713-722, 2004.
96. Stoner GD, and Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22, 1737-1746, 2001.
97. Hecht SS, Huang C, Stoner GD, Li J, Kenney PMJ, et al.: Identification of cyanidin glycosides as constituents of freeze-dried black raspberries which inhibit anti-benzo[a]pyrene-7,8-diol-9,10-epoxide induced NFκB and AP-1 activity. Carcinogenesis, in press.